Related Experiment Videos
Therapeutic use of antithrombin concentrate in sepsis
R Balk1, T Emerson, F Fourrier
1Department of Internal Medicine, Rush-Presbyterian St. Luke's Medical Center, Chicago, Illinois, USA.
Insights
Early detection of disseminated intravascular coagulation (DIC) in sepsis is crucial. Therapeutic antithrombin (AT) concentrate may improve outcomes if administered earlier, warranting further clinical trials.
Area of Science:
- Critical care medicine
- Hematology
- Pharmacology
Background:
- Sepsis, disseminated intravascular coagulation (DIC), and multiple organ dysfunction syndrome (MODS) are significant causes of mortality.
- Early diagnosis of DIC is essential for timely intervention.
- Antithrombin (AT) concentrate shows promise in treating sepsis-associated DIC.
Framework:
- Investigating the therapeutic potential of antithrombin (AT) concentrate for sepsis-associated DIC.
- Exploring the impact of earlier DIC identification and AT concentrate administration on patient outcomes.
- Evaluating the efficacy of AT concentrate compared to placebo in human clinical trials.
Implementation:
- Current fixed-bolus dosing of AT concentrate is weight-based.
- Development of user-friendly assays for plasma AT levels is needed for rapid results.
- Personalized AT concentrate administration can be refined with improved assays.
Implications:
- Earlier DIC detection and AT concentrate administration may improve sepsis outcomes.
- Further clinical trials are necessary to validate the efficacy of AT concentrate in sepsis.
- Optimizing AT concentrate use through rapid diagnostics can enhance patient-specific treatment.
Abstract:
Sepsis and its associated complications of disseminated intravascular coagulation (DIC) and multiple organ dysfunction syndrome (MODS) continue to be a major cause of morbidity and mortality. Improved detection of all forms of DIC is essential to assure earlier diagnosis. Studies already indicate that the therapeutic use of antithrombin (AT) concentrate may produce a more positive outcome for sepsis-associated DIC. If DIC could be identified earlier and AT concentrate could then be given earlier in the sepsis continuum, study results for the use of AT concentrate in humans might reveal a statistically significant difference versus placebo, and the efficacy of AT concentrate for this syndrome is more likely to be proved. Fixed-bolus doses of AT concentrate based on body weight are currently preferred, but improved, user-friendly assays for plasma AT levels would permit more rapid turnaround time for AT results and could help fine-tune the use of AT concentrate to the specific needs of each patient. Clinical trials involving the therapeutic use of AT concentrate in sepsis should continue, and it can be hoped that their design will reflect the concepts and conclusions offered by this panel of investigators.